Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumours
This study will evaluate dose escalation of melatonin in pediatric oncology patients with
relapsed solid tumours. The purpose of this study is to determine the safety of melatonin at
a dose up to 20 mg daily, as well as to determine the maximum tolerated dose of melatonin.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society